Trial reportRheumatology (Oxford, England)2025
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
Trial report in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab 150 mg in Patients With Active nr- axSpA to Evaluate the Safety,Tolerability and Efficacy up to 2 Yrs, Followed by an Opt Phase of Either 150 mg or 300 mg Randomized Dose Escalation for up to Another 2 Yrs
Who cites it
3 citing papers in PubMed.
- Multi-habitat radiomics on T2-FS MRI for identifying spatial patterns of axial spondyloarthritis-associated bone marrow edema.Clinical rheumatology · 2026Article
- Use of Artificial Intelligence in Rheumatoid Arthritis: Advancements and Novel Perspectives.Journal of clinical medicine · 2026Review
- External validation of SpineNetv2 deep learning system for automated lumbar spine MRI analysis: A multi-pathology diagnostic agreement study.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveTo evaluate the performance of machine learning (ML) models for the automated scoring of spinal MRI bone marrow oedema (BMO) in patients with axial spondyloarthritis (axSpA) and compare them with expert scoring.
methodsML algorithms using SpineNet software were trained and validated on 3483 spinal MRIs from 686 axSpA patients across two clinical trial datasets. The scoring pipeline involved (i) detection and labelling of vertebral bodies and (ii) classification of vertebral units for the presence or absence of BMO. Two models were tested: Model 1, without manual segmentation, and Model 2, incorporating an intermediate manual segmentation step. Model outputs were compared with those of human experts using kappa statistics, balanced accuracy, sensitivity, specificity and AUC.
resultsBoth models performed comparably to expert readers, regarding presence vs absence of BMO. Model 1 outperformed Model 2, with an AUC of 0.94 (vs 0.88), accuracy of 75.8% (vs 70.5%) and kappa of 0.50 (vs 0.31) using absolute reader consensus scoring as the external reference; this performance was similar to the expert inter-reader accuracy of 76.8% and kappa of 0.47 in a radiographic axSpA dataset. In a non-radiographic axSpA dataset, Model 1 achieved an AUC of 0.97 (vs 0.91 for Model 2), accuracy of 74.6% (vs 70%) and kappa of 0.52 (vs 0.27), comparable to the expert inter-reader accuracy of 74.2% and kappa of 0.46.
conclusionML software shows potential for automated MRI BMO assessment in axSpA, offering benefits such as improved consistency, reduced labour costs and minimized inter- and intra-reader variability.
trial registrationClinicaltrials.gov, http://clinicaltrials.gov, MEASURE 1 study (NCT01358175); PREVENT study (NCT02696031).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.